KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $1.5 billion.

  • Alnylam Pharmaceuticals' Cash & Equivalents rose 3548.7% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 3548.7%. This contributed to the annual value of $966.4 million for FY2024, which is 1859.7% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Cash & Equivalents is $1.5 billion, which was up 3548.7% from $1.1 billion recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Cash & Equivalents' 5-year high stood at $1.5 billion during Q3 2025, with a 5-year trough of $379.5 million in Q1 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $866.4 million (2022), whereas its average is $874.2 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Cash & Equivalents skyrocketed by 12025.01% in 2021 and then tumbled by 2282.33% in 2022.
  • Alnylam Pharmaceuticals' Cash & Equivalents (Quarter) stood at $822.2 million in 2021, then grew by 5.38% to $866.4 million in 2022, then dropped by 5.95% to $814.9 million in 2023, then rose by 18.6% to $966.4 million in 2024, then soared by 54.2% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.1 billion for Q2 2025, and $1.0 billion during Q1 2025.